Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verekitug (UPB-101) in Moderate-to-Severe COPD
2025-520488-42-00Phase 2Authorised
- Sponsor
- Upstream Bio
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 28
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Verekitug arm with Placebo arm (2 arms). Primary endpoint: Annualized rate of moderate or severe COPD exacerbation events. Planned start Sep 2025; status: authorised.
02
Drugs
vereckitug
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2025-520488-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520488-42-00.